Surgical oncologySONDAK, V. K.Journal of the American College of Surgeons. 1999, Vol 188, Num 2, pp 178-183, issn 1072-7515Article

New directions for medical artificial intelligenceSONDAK, V. K; SONDAK, N. E.Computers & mathematics with applications (1987). 1990, Vol 20, Num 4-6, pp 313-319, issn 0898-1221, 7 p.Article

A simple, inexpensive technique for clearing obstructed closed suction drainage cathetersSONDAK, V. K; MORTON, D. L.Surgery, gynecology & obstetrics. 1985, Vol 161, Num 6, pp 595-596, issn 0039-6087Article

Soft tissue sarcomas of the extremity and retroperitoneum : advances in managementSONDAK, V. K; ECONOMOU, J. S; EILBER, F. R et al.Advances in surgery (Chicago). 1991, Vol 24, pp 333-359, issn 0065-3411, 27 p.Article

In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assaySONDAK, V. K; KORN, E. L; KERN, D. H et al.International journal of cell cloning. 1988, Vol 6, Num 6, pp 378-391, issn 0737-1454Article

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapyPARAISO, Kht; FEDORENKO, I. V; CANTINI, L. P et al.British journal of cancer. 2010, Vol 102, Num 12, pp 1724-1730, issn 0007-0920, 7 p.Article

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2CHANG, A. E; ARUGA, A; CAMERON, M. J et al.Journal of clinical oncology. 1997, Vol 15, Num 2, pp 796-807, issn 0732-183XArticle

Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanomaFLAHERTY, L. E; LIU, P. Y; UNGER, J et al.American journal of clinical oncology. 1997, Vol 20, Num 6, pp 600-604, issn 0277-3732Article

Testing chemotherapeutic combinations in the human tumor colony ― forming assaySONDAK, V. K; KORN, E. L; MORTON, D. L et al.Journal of surgical oncology. 1988, Vol 37, Num 3, pp 156-160, issn 0022-4790Article

Clinical application of the thymidine incorporation assayKERN, D. H; SONDAK, V. K; MORGAN, C. R et al.Annals of clinical and laboratory science. 1987, Vol 17, Num 6, pp 383-388, issn 0091-7370Article

Evolution and clinical application of a rapid chemosensitivity assaySONDAK, V. K; BERTELSEN, C. A; KERN, D. H et al.Cancer. 1985, Vol 55, Num 6, pp 1367-1371, issn 0008-543XConference Paper

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanomaALGAZI, A. P; WEBER, J. S; DAUD, A. I et al.British journal of cancer. 2012, Vol 106, Num 1, pp 85-91, issn 0007-0920, 7 p.Article

Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent : Phase I studyBREWER, G. J; DICK, R. D; STRAWDERMAN, M et al.Clinical cancer research. 2000, Vol 6, Num 1, pp 1-10, issn 1078-0432Article

Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma : a southwest oncology group trialMARGOLIN, K. A; LIU, P. Y; WEISS, G. R et al.Journal of cancer research and clinical oncology. 1999, Vol 125, Num 5, pp 292-296, issn 0171-5216Article

Advances in melanoma therapyJOHNSON, T. M; YAHANDA, A. M; CHANG, A. E et al.Journal of the American Academy of Dermatology. 1998, Vol 38, Num 5, pp 731-741, issn 0190-9622, 1Article

A phase II trial of interleukin-2 and interferon-α in the treatment of metastatic colorectal carcinomaCHANG, A. E; CAMERON, M. J; SONDAK, V. K et al.Journal of immunotherapy with emphasis on tumor immunology. 1995, Vol 18, Num 4, pp 253-262, issn 1067-5582Article

Enhancing effect of interleukin 1α administration on antitumor effector T-cell development. DiscussionSONDAK, V. K; TUCK, M. K; SUYU SHU et al.Archives of surgery (Chicago, IL. 1960). 1991, Vol 126, Num 12, pp 1503-1509, issn 0004-0010Conference Paper

Chemosensitivity testing of human solid tumors: a review of 1582 assays with 258 clinical correlations = Test de chimiosensibilité des tumeurs solides humaines. Une revue de 1582 tests en corrélation avec 258 cas cliniquesBERTELSEN, C. A; SONDAK, V. K; MANN, B. D et al.Cancer. 1984, Vol 53, Num 6, pp 1240-1245, issn 0008-543XArticle

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanomaDAUD, A. I; XU, C; HWU, W.-J et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 3, pp 657-666, issn 0344-5704, 10 p.Article

A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicinTANG, H-J; QIAN, D; SONDAK, V. K et al.British journal of cancer. 2004, Vol 90, Num 6, pp 1285-1292, issn 0007-0920, 8 p.Article

Complete spontaneous regression of pulmonary metastatic melanomaWANG, T. S; LOWE, L; SMITH, J. W et al.Dermatologic surgery. 1998, Vol 24, Num 8, pp 915-919, issn 1076-0512Article

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma : A southwest oncology group studyMARGOLIN, K. A; LIU, P.-Y; FLAHERTY, L. E et al.Journal of clinical oncology. 1998, Vol 16, Num 2, pp 664-669, issn 0732-183XArticle

Malignant melanoma of the foot and ankleFORTIN, P. T; FREIBERG, A. A; REES, R et al.Journal of bone and joint surgery. American volume. 1995, Vol 77, Num 9, pp 1396-1403, issn 0021-9355Article

Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitroCHANG, A. E; YOSHIZAWA, H; SAKAI, K et al.Cancer research (Baltimore). 1993, Vol 53, Num 5, pp 1043-1050, issn 0008-5472Article

Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma : a Southwest oncology group studyFLETCHER, W. S; DANIELS, D. S; SONDAK, V. K et al.American journal of clinical oncology. 1993, Vol 16, Num 4, pp 359-362, issn 0277-3732Article